Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ ICU admission 77% Improvement Relative Risk c19hcq.org Güner et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 704 patients in Turkey Lower ICU admission with HCQ (not stat. sig., p=0.16) Güner et al., J. Infection and Public Health, doi:10.1016/j.jiph.2020.12.017 Favors HCQ Favors control
Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir
Güner et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.12.017
Güner et al., Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir,.., Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.12.017
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 824 hospitalized patients in Turkey showing lower ICU admission for HCQ vs. favipiravir.
risk of ICU admission, 77.3% lower, RR 0.23, p = 0.16, treatment 604, control 100, inverted to make RR<1 favor treatment, IPTW multivariate analysis, HCQ vs. favipiravir.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Güner et al., 29 Dec 2020, retrospective, Turkey, peer-reviewed, 23 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal of Infection and Public Health 14 (2021) 365–370 Contents lists available at ScienceDirect Journal of Infection and Public Health journal homepage: http://www.elsevier.com/locate/jiph Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir Rahmet Guner a , Imran Hasanoglu a,∗ , Bircan Kayaaslan a , Adalet Aypak b , Esragul Akinci c , Hurrem Bodur c , Fatma Eser a , Ayse Kaya Kalem a , Orhan Kucuksahin d , Ihsan Ates e , Aliye Bastug c , Yasemin Tezer Tekce b , Zeynep Bilgic b , Fahriye Melis Gursoy b , Hatice Nisa Akca b , Seval Izdes f , Deniz Erdem g , Emra Asfuroglu e , Habibe Hezer h , Hatice Kilic i , Musa Cıvak e , Sibel Aydogan j , Turan Buzgan a a Department of Infectious Disease and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey Department of Infectious Disease and Clinical Microbiology, Ankara City Hospital, Ankara, Turkey c Department of Infectious Disease and Clinical Microbiology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey d Department of Rheumatology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey e Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey f Department of Anaesthesiology and Reanimation, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey g Department of Anaesthesiology and Reanimation, Ankara City Hospital, Ankara, Turkey h Department of Pulmonary Diseases, Ankara City Hospital, Ankara, Turkey i Department of Pulmonary Diseases, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey j Department of Virology, Ankara City Hospital, Ankara, Turkey b a r t i c l e i n f o Article history: Received 11 November 2020 Received in revised form 10 December 2020 Accepted 15 December 2020 Keywords: COVID-19 Treatment Favipiravir Hydroxychloroquine ICU a b s t r a c t Background: In this study, we aimed to compare the intensive care unit (ICU) admission rate of hospitalized mild/moderate COVID-19 patients treated with hydroxychloroquine (HCQ), favipiravir, and HCQ plus favipiravir. Methods: Single center retrospective designed observational study conducted in Ankara City Hospital. Patients who were hospitalized between March 15, 2020 and June 1, 2020 in COVID-19 inpatient clinics with laboratory confirmed diagnosis of COVID-19 were included in the study. An inverse probability of treatment weighting (IPTW) for multiple treatment groups approach was used to balance the differences in several variables on admission. Results: Among 2441 patients hospitalized with diagnosis of COVID-19 during the study period, 824 were eligible for the analysis. Median age of patients was 42 (18−93 years). Among all, 347 (43.2%) of the patients had mild disease, 470 (56.8%) had pneumonia. Propensity scores ranged from 0.1841 to 0.9381 in the HCQ group, from 0.03643 to 0.29885 in the favipiravir group, and from 0.03542 to 0.56184 in the HCQ plus favipiravir group. After IPTW for multiple treatment groups was applied, all the covariates in the planned propensity score had weighted standardized effect sizes below 10% which were ranged from 0.005 to 0.092. Multivariate analysis of treatment effect (adjusted effect of treatment) was indicated that there is no statistically significant difference between HCQ, favipiravir, and HCQ plus favipiravir treatment. After using combination of SMOTE..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit